The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICLE 2022 | Focusing on allogeneic CAR T-cell therapies for myeloma
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, discusses the advantages of using allogeneic sources for chimeric antigen receptor (CAR) T-cell therapy, especially for the treatment of multiple myeloma. Patients with myeloma tend to be older and as result of their age and disease status, the T-cells will be dysfunctional and unsuitable for the production of CAR T-cell therapies. Allogeneic T-cells will enhance the efficacy of cell therapies and additionally reduce production costs. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
